Multicenter study comparing EUS‐guided hepaticogastrostomy and ERCP for malignant biliary obstruction in patients with accessible papillae
Takeshi Ogura,Hirotoshi Ishiwatari,Susumu Hijioka,Kotaro Takeshita,Junya Sato,Mamoru Takenaka,Tomohiro Fukunaga,Shunsuke Omoto,Nao Fujimori,Akihisa Ohno,Keiichi Hatamaru,Takaaki Tamura,Hajime Imai,Masanori Yamada,Akitoshi Hakoda,Hiroki Nishikawa,Masayuki Kitano
DOI: https://doi.org/10.1002/jhbp.12055
2024-07-19
Journal of Hepato-Biliary-Pancreatic Sciences
Abstract:Background One advantage of endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) is that it is difficult for reflux cholangitis, caused by duodenal pressure increasing due to duodenal obstruction, to occur. In addition, since stent deployment is performed away from the malignant stricture site, longer stent patency than with endoscopic retrograde cholangiopancreatography (ERCP) may be obtained. However, no study has previously compared EUS‐HGS and ERCP for patients without duodenal obstruction or surgically altered anatomy. The aim of the present study was to compare clinical outcomes between EUS‐HGS and ERCP in normal anatomy patients without duodenal obstruction. Method In the ERCP group, patients who initially underwent biliary drainage were included. In the EUS‐HGS group, patients who underwent EUS‐HGS due to failed biliary cannulation were included. Patients with an inaccessible papilla, such as with surgically altered anatomy or duodenal obstruction, were excluded. Results A total of 314 patients who underwent ERCP and EUS‐HGS were enrolled in this study. Of the 314 patients, 289 underwent biliary stenting under ERCP guidance, and 25 patients underwent biliary stenting under EUS‐HGS. After propensity score‐matching analysis, the adverse event rate tended to be lower in the EUS‐HGS group than in the ERCP group. Although overall survival was not significantly different between the EUS‐HGS and ERCP groups (p = .228), stent patency was significantly longer in the EUS‐HGS group (median 366.0 days) than in the ERCP group (median 76.5 days). Conclusions EUS‐HGS had a lower adverse event rate, shorter procedure time, and longer stent patency than ERCP in cases of normal anatomy without duodenal obstruction.
gastroenterology & hepatology,surgery